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LETTERS TO THE EDITOR
Angioplasty for Acute Myocardial
Infarction in Community Hospital
Without Surgical Back-Up:
Response to Wharton and Angelini
Publications “Should Guidelines Be
Changed?: Not Whether but When”
Guidelines evolve in response to rigorously acquired evidence-
based data. Thus, the validity of any guideline to describe a current
standard of care is dependent on the robustness of the database
from which it is derived. The recent publication by Wharton et al.
(1) and the accompanying editorial comment by Angelini (2) may
be the bell weather for a new guideline for the treatment of acute
myocardial infarction (MI) with coronary angioplasty in commu-
nity centers without on-site surgical back-up. The series of patients
with evolving MI who underwent emergency coronary angiogra-
phy with or without percutaneous coronary intervention (PCI)
reported by Wharton et al. (1) represent a successful experience
from a single, prospective clinical approach. However, in consid-
ering new guidelines for the treatment of patients with acute MI,
one must recognize that this isolated experience represents neither
a randomized clinical trial nor a prospective parallel comparison of
outcomes, achieved at facilities without cardiothoracic surgical
backup.
Before attempting to extrapolate such findings (1) to clinical
practice, several concerns merit discussion. As Wharton et al. (1)
note, clinicians will need “standards for the performance of primary
angioplasty for operators, laboratories and institutions.” Although
the “operators” in this report (1) are “experienced interventionalists
who regularly perform elective intervention at a tertiary surgical
center,” defining yearly volume, credentialing the operators, and
quantifying a satisfactory cumulative experience are all critical to
the process. Operators and credentialing committees should re-
member that 72% of all interventional procedures performed in the
U.S. were done by operators who performed #50 interventions
yearly (3). Recent data suggest that optimal outcomes (lowest
incidence of death and/or urgent revascularization) are achieved
with individual operator volumes exceeding 75 to 150 procedures
yearly (4–6). This “practice makes perfect” concept (7) has gained
broad support (8,9). It should be no surprise that the ACC/AHA
Task Force Committee has adhered to the recommendation for
performance of $75 interventional procedures yearly to maintain
competency (10). Extrapolation of results from studies without
such data may be misleading.
We agree with Wharton et al. (1) that there is a need to establish
“a nursing and technical catheterization laboratory staff (that must
be) experienced in handling acutely ill patients and comfortable
with interventional equipment.” The care of an acutely ill patient
with an evolving MI undergoing coronary angioplasty oftentimes
involves handling multiple IV drips, the placement of an intra-
aortic balloon pump, managing ventricular ectopy, and intubation
and ventilation. This requires an extremely experienced support
team (in addition to an experienced interventionalist), which is less
likely to be available in a hospital performing only primary
angioplasty procedures. As with operator experience, recent data
link institutional volume with procedural outcomes (4,11,12), such
that optimal procedural outcomes are achieved with institutional
volumes exceeding 600 interventional procedures yearly (6), a
volume unlikely to be achieved in hospitals performing only
primary coronary angioplasty. The qualifications and quality of the
technical staff in low volume institutions should be carefully
examined.
Although it is true, as Dr. Angelini indicates, that “coronary
stents are used in 60% to 80% of coronary angioplasty cases in
major interventional cardiology departments worldwide . . . surgi-
cal standby during coronary angioplasty seems out of touch with
reality and is certainly not cost effective,” the nature of surgical
standby has clearly changed. Whether surgery is on-site or 30 min
away, the central issue is whether hospitals without on-site surgery
will perform too few interventional procedures to ensure optimal
outcomes. More importantly, the availability of on-site surgical
standby is a surrogate for institutional volume and, to a large
extent, program quality. Similarly, merely equipping a laboratory
with stents does not negate the impact of operator quality, case
volume, or credentialing. It is noteworthy that a recent multivari-
able analysis identified low operator volumes as an independent
hazard for adverse clinical outcomes following elective coronary
stent deployment (12).
Guidelines generally do not address logistics. Wharton et al. (1)
remind us that the catheterization laboratory must be “well-
equipped with optimal imaging systems, resuscitative equipment,
intra-aortic balloon pump support, and a broad array of interven-
tional equipment.” The cost of maintaining a 24-h on-call team
and a well-equipped laboratory in a facility that performs only 50
to 100 procedures per year may be prohibitive. Furthermore, recent
data (13–15) suggest complementary benefit is derived from stents
and abciximab as adjunctive therapy during PCI for evolving MI.
The cost consequences of these recent valuable technologies must
also be considered.
Operators and community hospitals should be concerned about
the management of the few patients requiring emergency surgery.
Although formalized protocols for “immediate efficient transfer of
patients to the nearest cardiac surgical facility” are recommended
(1), details of such a protocol are not provided. In the MITI
Registry (16), patients undergoing primary angioplasty at facilities
without on-site surgery were less likely to receive bypass surgery.
The impact of this strategy on patient outcome is unclear.
Unequivocal guidelines for patients from mobile labs and the status
of ambulance availability for stable and unstable patients, as well as
criteria for having a physician in attendance during transfer, need
to be established. Time limits for availability of transport and
access to a tertiary center should be prespecified and followed.
Perhaps acute invasive interventions in diagnostic laboratories
without an on-site surgery will be superseded by recent advances in
pharmacotherapy with combination reduced dose fibrinolytic and
platelet GP IIb/IIIa therapy (17), making observations such as
those by Wharton et al. (1) obsolete (18). For example, the
restitution of normal, TIMI grade 3 flow in more than 70% of
patients within 60 min of instituting such combination therapy
(17,19) might be preferable in some community hospitals to
invasive reperfusion at an average of 94 min between hospital
arrival and first coronary angiogram (or 109 min until first balloon
catheter inflation noted in Wharton’s community hospital experi-
ence). Cost efficacy of these disparate community hospital-based
approaches to acute infarct reperfusion deserves further study.
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To date, large-scale community experience (MITI, NRMI) has
not reproduced the results of the randomized trials such that
mortality is similar between patients receiving thrombolytic ther-
apy and primary angioplasty. Furthermore, it is unclear how fast
reperfusion can be achieved in these settings. In NRMI-2, the
median “door to balloon” time for thrombolytic eligible patients
was 111 min. Only 10% of the patients were treated within 1 h and
approximately 60% between 1 and 3 h after hospital arrival (20).
The availability of catheterization laboratories is also a concern.
Although the majority of the Medicare population lives within 50
to 100 miles of a catheterization laboratory, not all laboratories
have angioplasty capabilities. Extending primary angioplasty to
diagnostic laboratories and withdrawing the need for on-site
surgery for elective angioplasty will promote low volume situations.
Based upon the paucity of data suggesting that primary angioplasty
in the community is superior to thrombolytic therapy in terms of
mortality and that volume and outcome are not as closely related in
the setting of primary angioplasty, it is not yet time to change a
public policy that will affect millions of people and cost billions of
dollars.
In the context of the above-noted concerns, the report by
Wharton et al. (1) on primary angioplasty for evolving MI in
community hospitals without cardiac surgical backup is provoca-
tive. However, in extrapolating this innovative approach to a
broadly applicable standard of care, we strongly urge caution. We
commend these operators for achieving competitive outcomes
compared with both historical and current tertiary medical center
results. We believe the answer to Dr. Angelini’s question, “Guide-
lines . . . Should they be changed?” is not “whether” but “when.”
Any substantive change in the present guidelines must be “evi-
denced based” and in the context of rigorously acquired and
analyzed data. As such, the AHA/ACC PTCA guidelines under-
going updating should provide current and valid recommendations
that are readily applicable to the broad scope of clinical practice by
interventional cardiologists.
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